Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.

Abstract: In one example, a semiconductor device can comprise a substrate, a device stack, first and second internal interconnects, and an encapsulant. The substrate can comprise a first and second substrate sides opposite each other, a substrate outer sidewall between the first substrate side and the second substrate side, and a substrate inner sidewall defining a cavity between the first substrate side and the second substrate side. The device stack can be in the cavity and can comprise a first electronic device, and a second electronic device stacked on the first electronic device. The first internal interconnect can be coupled to the substrate and the device stack. The encapsulant can cover the substrate inner sidewall and the device stack and can fill the cavity. Other examples and related methods are disclosed herein.

Abstract: Disclosed is an antibody for cancer treatment conjugated with a tumor environment-sensitive cleavable polyethylene glycol, wherein the use of the antibody for cancer treatment can suppress side effects of the antibody while maintaining therapeutic effects thereof.

Abstract: The present disclosure relates to a polycarbonate resin composition, and more particularly, to a polycarbonate resin composition containing 90 wt % to 99 wt % of a polycarbonate resin, 0.3 wt % to 0.7 wt % of an anthraquinone-based black dye, and 0.2 wt % to 1.0 wt % of an acrylic polymeric chain extender, and a molded article containing the same.

Abstract: A method for manufacturing a semiconductor device and a semiconductor device produced thereby. For example and without limitation, various aspects of this disclosure provide a method for manufacturing a semiconductor device, and a semiconductor device produced thereby, that comprises an interposer without through silicon vias.

Abstract: Disclosed are a method and apparatus for reusing wastewater. The method for reusing wastewater disclosed herein includes: generating a mixed wastewater by mixing multiple types of wastewater (S20); performing a first purification by passing the mixed wastewater through a flocculation-sedimentation unit (S40); performing a second purification by passing an effluent of the flocculation-sedimentation unit through a membrane bioreactor (MBR) (S60); performing a third purification by passing an effluent of the MBR through a reverse-osmosis membrane unit (S80); and reusing an effluent of the reverse-osmosis membrane unit as cooling water or industrial water (S100).

Abstract: A display device includes a first substrate, a first electrode above the first substrate, a pixel-defining film above the first electrode, and defining an emission area, a light-emitting layer above the first electrode and the pixel-defining film, a second electrode above the light-emitting layer, a thin-film encapsulation structure above the second electrode, and including an organic film defining an opening, and a color control layer above the thin-film encapsulation structure in the opening.

Abstract: The present invention may provide an organic electroluminescent device which exhibits low driving voltage as well as high efficiency by including an electron transporting layer material having an improved electron transporting ability.

Abstract: A vehicle height control apparatus includes an information acquisition device that acquires pressure data on a pressure inside an air tank storing compressed air and obstacle data on an obstacle in front of a vehicle, and a controller that calculates a target vehicle height based on the obstacle data, calculates a required distance required to reach the target vehicle height based on the pressure of the compressed air inside the air tank, and determines a vehicle height control timing, resolving a problem that the vehicle height is unnecessarily quickly controlled compared to the position of the obstacle, or is controlled after the vehicle passes through the obstacle to reduce the ride comfort.

Abstract: Devices and methods related to film bulk acoustic resonators. In some embodiments, a film bulk acoustic resonator can be manufactured by a method that includes forming a first electrode having a first lateral shape and providing a piezoelectric layer on the first electrode. The method can further include forming a second electrode having a second lateral shape on the piezoelectric layer such that the piezoelectric layer is between the first and second electrodes. The forming of the first electrode and the forming of the second electrode can include selecting and arranging the first and second lateral shapes to provide a resonator shape defined by an outline of an overlap of the first and second electrodes, such that the resonator shape includes N curved sections joined by N vertices of an N-sided polygon, and such that the resonator shape has no axis of symmetry.

Abstract: Disclosed are a method and apparatus for reusing wastewater. The method for reusing wastewater disclosed herein includes: generating a mixed wastewater by mixing multiple types of wastewater (S20); performing a first purification by passing the mixed wastewater through a flocculation-sedimentation unit (S40); performing a second purification by passing an effluent of the flocculation-sedimentation unit through a membrane bioreactor (MBR) (S60); performing a third purification by passing an effluent of the MBR through a reverse-osmosis membrane unit (S80); and reusing an effluent of the reverse-osmosis membrane unit as cooling water or industrial water (S100).

Abstract: Power semiconductor devices comprise a gate pad, a plurality of gate fingers, and a first gate resistor and a first switch that are coupled between the gate pad and the gate fingers.

Abstract: A stacked semiconductor device includes at least one upper chip including a plurality of channels each including first and second pseudo-channels; and a plurality of transfer control circuits respectively corresponding to the channels and each configured to output channel commands according to a channel designation signal designating one of the first and second pseudo-channels and a location information signal indicating a location of a corresponding channel of the channels, and transmit first and second data words between the corresponding channel and a lower chip according to the channel commands.

Abstract: A semiconductor device includes a semiconductor layer structure comprising a source/drain region, a gate dielectric layer on the semiconductor layer structure, and a gate electrode on the gate dielectric layer. The source/drain region comprises a first portion comprising a first dopant concentration and a second portion comprising a second dopant concentration. The second portion is closer to a center of the gate electrode than the first portion.

Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating a brain disease, comprising a stem cell-derived exosome surface-modified with a compound capable of binding to dopamine receptors or L-amino acid transporters as an active ingredient. The stem cell-derived exosome according to the present disclosure selectively binds to dopamine receptors (D2) overexpressed as autoreceptors in dopaminergic neurons in the substantia nigra through surface modification. Thereby, local accumulation in dopaminergic neurons is possible. In addition, it was identified that the stem cell-derived exosome exhibited an excellent neuron protective effect and neuron death inhibitory effect. Accordingly, the surface-modified stem cell-derived exosome according to the present disclosure is expected to be usefully used as a composition for preventing or treating a brain disease including Parkinson's disease and Alzheimer's disease.

Abstract: The present disclosure relates to a composition and a kit for colonization of external probiotics in the gut through bioorthogonal click chemistry. The composition or kit for colonization of external probiotics in the gut according to the present disclosure has the effects of overcoming colonization resistance, which is the limitation of existing external probiotics caused by physical discharge and indigenous bacteria, by linking surface-modified external probiotics to the intestinal mucosa into which a bioorthogonal functional group has been introduced, and beneficially changing the intestinal environment by long-term colonization of various external probiotics, such as lactic acid bacteria, bifidobacteria, and yeast. Accordingly, the present disclosure is expected to be effectively used for the development of various medicines and functional foods using probiotics.

Abstract: Disclosed herein is a reactor including a reactor vessel and a containment vessel configured to surround the reactor vessel. The containment vessel includes a thermal radiation shield disposed on an inner wall, and a gap between the reactor vessel and the containment vessel is in an atmospheric pressure and air atmosphere state.

Abstract: The present invention relates to a peptide for cancer immunotherapy that disrupts tumor-derived vesicles and a use thereof. The peptide according to the present invention has an ?-helical structure, inhibits T-cell functional impairment caused by tumor-derived vesicles and controls the formation of a tumor microenvironment as an immunosuppressive environment by disrupting the tumor-derived vesicles, and has effects of not only enhancing cancer immunotherapy activity but also inhibiting the metastasis of cancer cells through co-administration with an immune checkpoint inhibitor. Additionally, when the peptide is modified with PEG through a pH-sensitive linker, it has effects of increasing the stability of the peptide in vivo, and disrupting tumor-derived vesicles under the pH condition of the tumor microenvironment.

Abstract: According to an embodiment, a system includes at least one change detecting device that includes a map information storage unit receiving a high-definition map including a property of each road facility object and spatial coordinates of a feature point from a map updating server and storing the received high-definition map, an object coordinates obtaining unit recognizing at least one road facility object from the road image and obtaining a property of the recognized object and spatial coordinates of a feature point. and a changed object detecting unit comparing the property of the recognized object and the spatial coordinates of the feature point with the high-definition map and, if a change object is detected, transmitting object change information including a property and feature point spatial coordinates of the change object to the map updating server.

Abstract: The present invention relates to an antibody-drug conjugate comprising an exosome secretion inhibitor conjugated to an antibody for inhibiting immune checkpoints, and the use thereof for treating cancer. An antibody-drug conjugate according to the present invention is maintained, in normal tissue, in a form in which a drug is conjugated to an antibody, and releases the drug upon reaching a cancer microenvironment, thereby inhibiting the secretion of cancer exosomes that cause an immunosuppressive mechanism. Thus the antibody-drug conjugate exhibits high therapeutic efficacy and can remarkably increase the objective response rate to an immune checkpoint inhibitor.